Skip to main content

Table 2 Correlation of FGF-23 with continuous characteristics

From: FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI

Items FGF-23
P value Spearman r
Age 0.199 0.088
BMI 0.113 0.109
MAP 0.378 0.061
FBG < 0.001 0.245
IRI < 0.001 0.294
Scr < 0.001 0.381
SUA < 0.001 0.287
TG 0.093 0.115
TC 0.535 0.043
LDL-C 0.006 0.187
HDL-C 0.009 − 0.179
HsCRP < 0.001 0.377
ESR 0.448 0.052
WBC 0.455 − 0.051
Neutrophil 0.943 − 0.005
LVEF < 0.001 − 0.272
cTnI < 0.001 0.436
NT-proBNP < 0.001 0.400
Stenosis degree of target lesion 0.008 0.182
Length of target lesion 0.321 0.068
  1. Boldface represented P < 0.05
  2. FGF-23 fibroblast growth factor 23, BMI body mass index, MAP mean arterial pressure, FBG fasting blood-glucose, IRI insulin resistance index, Scr serum creatinine, SUA serum uric acid, TG triglyceride, TC total cholesterol, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, HsCRP high-sensitivity C-reactive protein, ESR erythrocyte sedimentation rate, WBC white blood cell, LVEF left ventricular ejection fraction, cTnI cardiac troponin I, NT-proBNP N-terminal-proB-type natriuretic peptide